Atezolizumab is a humanized immunoglobulin monoclonal antibody that selectively binds to PD-L1 to block PD-1/PD-L1 interactions, leading to sustained activation of tumor reactive T cells for potent anti-tumor responses [10]. Here, CD274 is linked to neoplasm.